INVEST
min $100
At Biostate AI, we envision a world where healthcare is uniquely tailored to each individual through the integration of AI and genomics.
We are revolutionizing the very future of medicine—where diseases are predicted before they emerge, treatments are tailored to your unique genetic makeup, and therapies achieve maximum efficacy with minimal side effects.
Imagine a future where health data empowers individuals and physicians alike to make life-saving decisions with precision, confidence, and clarity. This is not a distant dream—it’s the reality we are building today.
In just 2 years, Biostate AI has rapidly scaled precision medicine—analyzing 8,000+ clinical samples, partnering with 66 hospitals, and filing 12 patents.
With facilities in the U.S., China, and India, we are building one of the largest RNAseq datasets, expected to surpass 5 million samples by 2028 (projections not guaranteed). Our global reach enables cost-effective genomic data collection, accelerating real-world clinical adoption.
Together with our hospital and research partners, we are laying the foundation for AI-driven, personalized healthcare at scale!
At Biostate AI, we have already achieved significant breakthroughs that validate the power of our technology. Our BIRT technology reduces RNAseq costs fivefold, making high-quality genomic data more accessible and scalable than ever before.
In preliminary studies, our AI models have demonstrated remarkable clinical accuracy. For leukemia (AML/ALL), our system effectively stratifies patients into high- and low-risk groups, with high-risk patients being more than twice as likely to relapse. This critical insight helps oncologists identify those who may require more aggressive treatments, such as bone marrow transplants.
In drug safety research, our models have achieved 89% accuracy in predicting liver toxicity in rat models, enabling safer and more efficient pharmaceutical development.
By combining cutting-edge AI with real-world clinical validation, Biostate AI is redefining precision medicine—making advanced diagnostics faster, more accurate, and significantly more affordable!
Our leadership team brings together deep expertise in AI, genomics, and healthcare. Co-founders David Zhang and Ashwin Gopinath have established track records in biotech innovation and AI development, backed by leading investors from Anthropic, 10x Genomics, Twist Biosciences, etc.
Our Scientific Advisory Board consists of leading experts from institutions like MD Anderson Cancer Center, Harvard Medical School, and Baylor College of Medicine, ensuring our technology adheres to the highest scientific and clinical standards.
Our AI-powered genomics enables us to predict diseases before symptoms appear, personalize treatments to maximize effectiveness and assist physicians in making life-saving decisions with precision.
This is your opportunity to be part of a healthcare revolution! By investing in Biostate AI, you're joining our mission to transform bold visions into real-life solutions.
With your support, we can:
(1) Accelerate the conversion of samples to RNA data for AI training
(2) Establish additional academic and clinical collaborations
(3) Conduct clinical trials to obtain FDA approval for our AI tests, bringing their benefits to patients.
Together, we can reshape the future of healthcare and make precision medicine accessible worldwide.
*Investment Note: We have set an individual investment cap of $5000 to enable broader participation in Biostate AI's journey. If you believe in our mission, we encourage you to share this opportunity with others.
